Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060996 · ClinicalTrials.gov registry record · Phase 3
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
A Phase 3 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00060996: Clinical Trial Phase 3 study, sponsored by United Therapeutics.
NCT00060996 is a Phase 3 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060996, a Phase 3 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.
Interventions
- DRUG Remodulin® (treprostinil sodium) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
Why NCT00060996 stopped before completion
NCT00060996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Remodulin® (treprostinil sodium) Injection is the first listed.
NCT00060996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060996 about?
NCT00060996 is a clinical study titled "Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures". The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance...
What is the current status of trial NCT00060996?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2003-02. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00060996?
The interventions under investigation include: Remodulin® (treprostinil sodium) Injection (DRUG).
Who is sponsoring clinical trial NCT00060996?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00060996's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia